|
| 37292835 | Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk Stratification. | bioRxiv | 2023 |
| 37895201 | Complex Genomic Rearrangements Involving <i>ETV6</i>::<i>ABL1</i> Gene Fusion in an Individual with Myeloid Neoplasm. | Genes (Basel) | 2023 |
| 37992684 | Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. | Cell Rep Med | 2023 |
| 37572683 | Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. | Lancet Haematol | 2023 |
| 37678052 | Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults. | J Geriatr Oncol | 2023 |
| 37815132 | The FLT3<sup>N701K</sup> mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib. | Am J Hematol | 2023 |
| 35247612 | Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. | Transplant Cell Ther | 2022 |
| 35637252 | Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. | Blood Cancer J | 2022 |
| 35395091 | The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms. | Mol Cancer Ther | 2022 |
| 35849791 | Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia. | J Clin Oncol | 2022 |
| 35130342 | Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. | Blood Adv | 2022 |
| 33059507 | Therapy for acute myelogenous leukemia revisited: moving away from a one-size-fits-all approach. | Expert Rev Anticancer Ther | 2021 |
| 33626861 | The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i> and detectable in clinical samples prior to treatment. | Haematologica | 2021 |
| 33707421 | Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia. | Nat Commun | 2021 |
| 33666651 | Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. | Blood Adv | 2021 |
| 34103301 | Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. | Clin Cancer Res | 2021 |
| 34297319 | Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. | Clin Pharmacokinet | 2021 |
| 31493541 | Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients. | Biol Blood Marrow Transplant | 2020 |
| 32040554 | Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. | Blood Adv | 2020 |
| 33425766 | <i>FLT3</i> Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. | Front Oncol | 2020 |
| 32862867 | FLT3 Inhibition in Acute Myeloid Leukemia. | Clin Lymphoma Myeloma Leuk | 2020 |
| 32304015 | Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. | Clin Pharmacokinet | 2020 |
| 32330242 | A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. | Blood Adv | 2020 |
| 31088841 | Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. | Cancer Discov | 2019 |
| 31808872 | The growing landscape of FLT3 inhibition in AML. | Hematology Am Soc Hematol Educ Program | 2019 |
| 30733203 | Roman warfare: targeting of support cells in AML. | Blood | 2019 |
| 29859851 | Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. | Lancet Oncol | 2018 |
| 28490572 | Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. | Blood | 2017 |
| 27158668 | The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. | JCI Insight | 2016 |
| 26490487 | Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. | Leuk Lymphoma | 2016 |
| 26511402 | Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib. | Leukemia | 2016 |
| 26585411 | Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. | Leukemia | 2016 |
| 25243620 | Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. | Bone Marrow Transplant | 2015 |
| 26108694 | FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. | Leukemia | 2015 |
| 25847190 | Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. | Cancer Discov | 2015 |
| 25765758 | Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. | Eur J Med Chem | 2015 |
| 25776193 | A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. | Clin Lymphoma Myeloma Leuk | 2015 |
| 24374145 | Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. | Leuk Res | 2014 |
| 25456130 | Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. | Cell Rep | 2014 |
| 25531068 | Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. | Elife | 2014 |
| 24894413 | Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. | J Geriatr Oncol | 2014 |
| 24623852 | Crenolanib is a selective type I pan-FLT3 inhibitor. | Proc Natl Acad Sci U S A | 2014 |
| 24682858 | FLT3 inhibitors in AML: are we there yet? | Curr Hematol Malig Rep | 2014 |
| 23430109 | Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. | Blood | 2013 |
| 24324154 | Disease diversity and FLT3 mutations. | Proc Natl Acad Sci U S A | 2013 |
| 23714533 | The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. | Am Soc Clin Oncol Educ Book | 2013 |
| 22504184 | Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. | Nature | 2012 |
| 24451819 | Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia. | Am Soc Clin Oncol Educ Book | 2012 |
| 21948230 | Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia. | Clin Cancer Res | 2011 |
| 22160023 | Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. | Hematology Am Soc Hematol Educ Program | 2011 |